vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Trading Down 7.7 %

Shares of VTVT opened at $20.99 on Wednesday. vTv Therapeutics has a 12 month low of $12.12 and a 12 month high of $30.99. The firm has a fifty day simple moving average of $16.76 and a 200 day simple moving average of $15.40. The stock has a market capitalization of $66.96 million, a price-to-earnings ratio of -4.63 and a beta of 1.07.

Institutional Investors Weigh In On vTv Therapeutics

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics in the 4th quarter valued at approximately $25,000. Geode Capital Management LLC raised its holdings in vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the last quarter. Finally, FMR LLC bought a new position in vTv Therapeutics during the 3rd quarter worth approximately $2,402,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.